PERSPECTA

News from every angle

← Back to headlines

Clearmind and SciSparc Collaboration Advances MDMA-Related IP for PTSD Treatment

The collaboration between NeuroThera-Clearmind and SciSparc is advancing MDMA-N-acylethanolamines intellectual property for treating PTSD, supported by increasing U.S. federal interest in psychedelic innovation.

24 Aug, 12:51 — 24 Aug, 12:51
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual17h ago

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - Taiwan News

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation  Taiwan News

Read full article →

Related Stories

Europe's Heatwaves Cause At Least 35,000 Excess Deaths

1h ago

Study Links Breakfast Timing to Lifespan

3h ago

Exploring Mental Health and Wellness Beyond Traditional Therapy, Including Sound Therapy

6h ago

Health Company Admits Maradona Test Mix-Up in Death Trial

7h ago